Minnesota
Quiénes somos
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Un estudio de combinación de dosis fija de nivolumab-relatlimab frente a regorafenib o TAS-102 en participantes con cáncer colorrectal metastásico de última línea
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Estudio de la plataforma TAPISTRY (Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You)
Estudio de cánceres gastrointestinales metastásicos tratados con linfocitos infiltrantes tumorales en los que se inhibe el gen que codifica el punto de control inmunitario intracelular CISH mediante ingeniería genética CRISPR.
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
Estudio de fase 3 de MRTX849 con cetuximab frente a quimioterapia en pacientes con cáncer colorrectal avanzado con mutación KRAS G12C (KRYSTAL-10)
